A Newly Developed Artificial Chemical Receptor Will Help Viral Transduction for T-Cell Engineering

Chimeric antigen receptor T cell (CAR-T) otherwise known as engineering T cell immunotherapy and T cell receptor T cell (TCR-T) has emerged as a viable therapeutic strategy for treating tumors.

The genetic manipulation of primary T cell, however, remains inefficient, particularly during the clinical manufacturing process. Urgent needs have arisen to develop a reliable technique for the preparation of engineered T cells.

At the Shenzhen Institutes of Advanced Technology (SIAT) of the Chinese Academy of Sciences, a team of researchers led by Prof. CAI Lintao as well as other collaborators have developed a 'safe efficient and universal' technique based on bioorthogonal chemistry and glycol-metabolic labeling for viral-mediated engineered T cell manufacturing. These researchers published their discoveries in Advanced Functional Materials.

The researchers attached the functional azide motifs on T cell surfaces, for this approach, via the intrinsic glycometabolism of exogenous azide-glucose, thereby serving as an artificial ligand for viral binding. They also coated the complementary functional moiety dienzocyclooctyne (DBCO)/-conjugated PEI1.8K (PEI-DBCO) on the lentiviral surface, which strengthened the virus-T cell interaction through DBCO/azide bioorthogonal chemistry.

CAI said that they discovered that this artificial chemical receptor effectively facilitated viral bindings to T cells and elevated the transduction efficiency of the lentivirus from 20 percent to 80 percent without any effect on T cell proliferation activity. The alteration on this artificial chemical was also suitable for launching other heterologous genes into T cells, including GPF, CAR, and TCR, indicating an excellent potency for universal T cell engineering.

The demonstration on the technique confirmed it to be safe for human primary T cells as well, without interference from cell expansion or antitumor functions. When the scientists place it into the CAR-T preparation, the PEI-DBCO/azide-glucose system considerably increased the yield of CAR T cells and boosted their antitumor effect both in vitro and in the B lymphoma xenograft mouse model with a small amount of CAR-T cells, consequently reducing clinical adverse effects.

CAI stated that the labeling strategy of the artificial chemical is a secure, safe, and effective upgrade for viral-based gene manipulation of human primary T cells, thus showing great potential for clinical engineered T lymphocyte manufacturing, including CAR-T and TCR-T cell therapy.

The corresponding author of the paper, Prof. CAI was selected as a Fellow of the American Institute for Medical and Biological Engineering (AIMBE) on March 25 at the American Academy of Sciences in Washington, a nonprofit institute established in 1991, for his involvements relating optical probes and biomimetic drug delivery systems in the fields of nanomedicine and cancer theranostics.

Join the Discussion

Recommended Stories

Real Time Analytics